119 related articles for article (PubMed ID: 21812508)
1. Romidepsin: in the treatment of T-cell lymphoma.
Yang LP
Drugs; 2011 Jul; 71(11):1469-80. PubMed ID: 21812508
[TBL] [Abstract][Full Text] [Related]
2. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
Foss F; Horwitz S; Pro B; Prince HM; Sokol L; Balser B; Wolfson J; Coiffier B
J Hematol Oncol; 2016 Mar; 9():22. PubMed ID: 26965915
[TBL] [Abstract][Full Text] [Related]
3. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.
Bates SE; Eisch R; Ling A; Rosing D; Turner M; Pittaluga S; Prince HM; Kirschbaum MH; Allen SL; Zain J; Geskin LJ; Joske D; Popplewell L; Cowen EW; Jaffe ES; Nichols J; Kennedy S; Steinberg SM; Liewehr DJ; Showe LC; Steakley C; Wright J; Fojo T; Litman T; Piekarz RL
Br J Haematol; 2015 Jul; 170(1):96-109. PubMed ID: 25891346
[TBL] [Abstract][Full Text] [Related]
4. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
Foss F; Pro B; Miles Prince H; Sokol L; Caballero D; Horwitz S; Coiffier B
Cancer Med; 2017 Jan; 6(1):36-44. PubMed ID: 27981793
[TBL] [Abstract][Full Text] [Related]
5. Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions.
Akilov OE; Grant C; Frye R; Bates S; Piekarz R; Geskin LJ
Br J Dermatol; 2012 Jul; 167(1):194-7. PubMed ID: 22372971
[TBL] [Abstract][Full Text] [Related]
6. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.
Horwitz S; Coiffier B; Foss F; Prince HM; Sokol L; Greenwood M; Caballero D; Morschhauser F; Pinter-Brown L; Iyer SP; Shustov A; Nichols J; Balser J; Balser B; Pro B
Ann Oncol; 2015 Apr; 26(4):774-779. PubMed ID: 25605745
[TBL] [Abstract][Full Text] [Related]
7. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report.
Ritchie D; Piekarz RL; Blombery P; Karai LJ; Pittaluga S; Jaffe ES; Raffeld M; Janik JE; Prince HM; Bates SE
Haematologica; 2009 Nov; 94(11):1618-22. PubMed ID: 19608677
[TBL] [Abstract][Full Text] [Related]
8. Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma.
Frye R; Myers M; Axelrod KC; Ness EA; Piekarz RL; Bates SE; Booher S
Clin J Oncol Nurs; 2012 Apr; 16(2):195-204. PubMed ID: 22459529
[TBL] [Abstract][Full Text] [Related]
9. Use of class I histone deacetylase inhibitor romidepsin in combination regimens.
Petrich A; Nabhan C
Leuk Lymphoma; 2016 Aug; 57(8):1755-65. PubMed ID: 27118119
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study.
Iyer SP; Huen A; Ai WZ; Jagadeesh D; Lechowicz MJ; Okada C; Feldman TA; Ghione P; Alderuccio JP; Champion R; Kim SH; Mohrbacher A; Routhu KV; Barde P; Nair AM; Haverkos BM
Haematologica; 2024 Jan; 109(1):209-219. PubMed ID: 37439343
[TBL] [Abstract][Full Text] [Related]
11. Improving gastrointestinal quality of life: romidepsin to tucidinostat in a case of angioimmunoblastic T cell lymphoma.
Isoda A; Terasaki Y; Kanaya S; Saito A
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38199657
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors.
Gaillard SL; Zahurak M; Sharma A; Durham JN; Reiss KA; Sartorius-Mergenthaler S; Downs M; Anders NM; Ahuja N; Rudek MA; Azad N
Cancer; 2019 Aug; 125(16):2837-2845. PubMed ID: 31012962
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
Ryu Tiger YK; Jain S; Barta SK; Tolu S; Estrella B; Sawas A; Lue JK; Francescone MM; Pro B; Amengual JE
Leuk Lymphoma; 2024 Jun; 65(6):736-745. PubMed ID: 38517235
[TBL] [Abstract][Full Text] [Related]
14. Phase II Trial Using Romidepsin after Gemcitabine, Dexamethasone, and Cisplatin Therapy in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Study Protocol.
Yamasaki S; Kada A; Nagai H; Yoshida I; Choi I; Saito AM; Iwasaki H
Acta Med Okayama; 2019 Oct; 73(5):469-474. PubMed ID: 31649375
[TBL] [Abstract][Full Text] [Related]
15. The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors in Vivo.
Paillas S; Then CK; Kilgas S; Ruan JL; Thompson J; Elliott A; Smart S; Kiltie AE
Int J Radiat Oncol Biol Phys; 2020 May; 107(1):212-221. PubMed ID: 31987970
[TBL] [Abstract][Full Text] [Related]
16. A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment.
Nettersheim D; Jostes S; Fabry M; Honecker F; Schumacher V; Kirfel J; Kristiansen G; Schorle H
Oncotarget; 2016 Nov; 7(46):74931-74946. PubMed ID: 27572311
[TBL] [Abstract][Full Text] [Related]
17. Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma.
Ruan J; Zain J; Palmer B; Jovanovic B; Mi X; Swaroop A; Winter JN; Gordon LI; Karmali R; Moreira J; Petrich AM; Pro B
Blood Adv; 2023 Oct; 7(19):5771-5779. PubMed ID: 37327113
[TBL] [Abstract][Full Text] [Related]
18. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
Barbarotta L; Hurley K
J Adv Pract Oncol; 2015; 6(1):22-36. PubMed ID: 26413372
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Treatment with Romidepsin in Patients with Peripheral T-Cell Lymphoma.
Irlé C; Weintraub J
Case Rep Hematol; 2016; 2016():8175957. PubMed ID: 27648317
[TBL] [Abstract][Full Text] [Related]
20. Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma.
Kalac M; Jain S; Tam CS; Xiao Z; Montanari F; Kanakry J; Huber BD; Goldfinger M; O'Connor OA; Marchi E
Blood Adv; 2023 Jul; 7(14):3760-3763. PubMed ID: 36790924
[No Abstract] [Full Text] [Related]
[Next] [New Search]
